Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma

Blood

Volumn 122, Issue 6, 2013, Pages 943-950

  Krejsgaard, Thorbjørn ^a   Litvinov, Ivan V ^b   Wang, Yang ^c,d   Xia, Lixin ^c,e   Willerslev Olsen, Andreas ^a   Koralov, Sergei B ^f   Kopp, Katharina L ^a   Bonefeld, Charlotte M ^a   Wasik, Mariusz A ^g   Geisler, Carsten ^a   Woetmann, Anders ^a   Zhou, Youwen ^c   Sasseville, Denis ^b   Odum, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; JANUS KINASE; STAT3 PROTEIN; CYTOKINE; STAT3 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE RELEASE; DERMATITIS; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN DEFECT; T-LYMPHOCYTE CELL LINE; BIOPSY; GENE EXPRESSION REGULATION; LEUKEMIA CELL LINE; METABOLISM; MYCOSIS FUNGOIDES; PATHOLOGY; SKIN; TUMOR CELL LINE;

BIOPSY; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-17; JANUS KINASES; JURKAT CELLS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MYCOSIS FUNGOIDES; SKIN; STAT3 TRANSCRIPTION FACTOR;

EID: 84882787087     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-480889     Document Type: Article

References (59)

1. Willemze R, Jaffe ES, Burg G, et al. WHOEORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
2. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet. 2008;371(9616):945-957.
3. Dummer R, Goldinger SM, Cozzio A, French LE, Karpova MB. Cutaneous lymphomas: molecular pathways leading to new drugs. J Invest Dermatol. 2012;132(3):517-525.
4. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996;132(11): 1309-1313.
5. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol. 1999;135(1): 26-32.
6. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149-162.
7. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8): 556-567.
8. Cheung PF, Wong CK, Lam CW. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol. 2008;180(8): 5625-5635.
9. Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30(1): 108-119.
10. Fujie H, Niu K, Ohba M, et al. A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells. Inflammation. 2012;35(3): 1119-1131.
11. Cir ée A, Michel L, Camilleri-Bröet S, et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer. 2004;112(1):113-120.
12. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol. 2011;131(6): 1331-1338.
13. Litvinov IV, Jones DA, Sasseville D, Kupper TS. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res. 2010;16(7):2106-2114.
14. Shin J, Monti S, Aires DJ, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood. 2007;110(8):3015-3027.
15. Woetmann A, Lovato P, Eriksen KW, et al. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood. 2007;109(8):3325-3332.
16. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol. 2000;157(4):1137-1146.
17. Wasik MA, Seldin DC, Butmarc JR, et al. Analysis of IL-2, IL-4 and their receptors in clonally-related cell lines derived from a patient with a progressive cutaneous T-cell lymphoproliferative disorder. Leuk Lymphoma. 1996;23(1-2):125-136.
18. Geisler C, Schøller J, Wahi MA, Rubin B, Weiss A. Association of the human CD3-zeta chain with the alpha beta-T cell receptor/CD3 complex. Clues from a T cell variant with a mutated T cell receptor-alpha chain. J Immunol. 1990;145(6): 1761-1767.
19. Geisler C, Dietrich J, Nielsen BL, et al. Leucinebased receptor sorting motifs are dependent on the spacing relative to the plasma membrane. J Biol Chem. 1998;273(33):21316-21323.
20. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood. 2009;113(23): 5896-5904.
21. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia. 2008;22(12):2230-2239.
22. Olsen E, Vonderheid E, Pimpinelli N, et al; ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
23. Zhang Y, Wang Y, Yu R, et al. Molecular markers of early-stage mycosis fungoides. J Invest Dermatol. 2012;132(6):1698-1706.
24. Wang Y, Su M, Zhou LL, et al. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood. 2011;117(14):3826-3835.
25. Kennah E, Ringrose A, Zhou LL, et al. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells. Blood. 2009;113(19):4646-4655.
26. Ringrose A, Zhou Y, Pang E, et al. Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas. Leukemia. 2006;20(9):1593-1601.
27. Su MW, Dorocicz I, Dragowska WH, et al. Aberrant expression of T-plastin in Sezary cells. Cancer Res. 2003;63(21):7122-7127.
28. Litvinov IV, Kupper TS, Sasseville D. The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression. Exp Dermatol. 2012;21(12):964-966.
29. Litvinov IV, Zhou Y, Kupper TS, Sasseville D. Loss of BCL7A expression correlates with poor disease prognosis in patients with early-stage cutaneous T-cell lymphoma. Leuk Lymphoma. 2013;54(3):653-655.
30. Liu XK, Lin X, Gaffen SL. Crucial role for nuclear factor of activated T cells in T cell receptormediated regulation of human interleukin-17. J Biol Chem. 2004;279(50):52762-52771.
31. Sommer VH, Clemmensen OJ, Nielsen O, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia. 2004;18(7):1288-1295.
32. Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA. 1996;93(17):9148-9153.
33. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al. Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia. 2006;20(10): 1759-1766.
34. Li J, Li D, Tan Z. The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris. J Huazhong Univ Sci Technolog Med Sci. 2004;24(3):294-296.
35. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006; 203(12):2577-2587.
36. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183-3194.
37. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950-957.
38. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-1211.
39. Miyagaki T, Sugaya M, Fujita H, et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol. 2010;130(9):2304-2311.
40. Ge D, You Z. Expression of interleukin-17RC protein in normal human tissues. Int Arch Med. 2008;1(1):19.
41. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7): 857-866.
42. Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051-5060.
43. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-4739.
44. van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2009;113(1):127-136.
45. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010; 116(5):767-771.
46. Miyagaki T, Sugaya M, Suga H, et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res. 2011;17(24): 7529-7538.
47. Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. Leukemia. 2012;26(3): 424-432.
48. Abraham RM, Zhang Q, Odum N, Wasik MA. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther. 2011;12(12):1019-1022.
49. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620-2627.
50. Chauhan SK, Jin Y, Goyal S, et al. A novel prolymphangiogenic function for Th17/IL-17. Blood. 2011;118(17):4630-4634.
51. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183(6):2593-2603.
52. Pedersen IH, Willerslev-Olsen A, Vetter-Kauczok C, et al. Vascular endothelial growth factor receptor-3 expression in mycosis fungoides. Leuk Lymphoma. 2013;54(4):819-826.
53. Karpova MB, Fujii K, Jenni D, Dummer R, Urosevic-Maiwald M. Evaluation of lymphangiogenic markers in Sézary syndrome. Leuk Lymphoma. 2011;52(3):491-501.
54. Mazur G, Wózniak Z, Wróbel T, Maj J, Kuliczkowski K. Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res. 2004;10(1):34-36.
55. Vacca A, Moretti S, Ribatti D, et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer. 1997; 33(10):1685-1692.
56. Kopp KL, Kauczok CS, Lauenborg B, et al. COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia. 2010;24(6): 1179-1185.
57. Kopp KL, Dabelsteen S, Krejsgaard T, et al. COX-2 is a novel target in therapy of mycosis fungoides. Leukemia. 2010;24(12):2127-2129.
58. Wu XS, Lonsdorf AS, Hwang ST. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol. 2009; 129(5):1115-1119.
59. Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011;64(2): 352-404.